c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.

c-Met-IN-23 inhibits HGF-induced cell proliferation with IC 50 values of 12.4, 3.06, 19.30, and 16.85 µM for HT29, HepG2, MCF7, and MDA-MB-231 cells, respectively. At concentrations between 0.3 and 150 µM for 30 minutes, c-Met-IN-23 can block P-gp and MRP1/2 pumps in HepG2 and BxPC3 cells. Additionally, a concentration of 3 µM for 24 hours increases the expression of P-gp in HepG2 and BxPC3 cells and the expression of MRP1 and MRP2 in BxPC3 cells, while inhibiting P-gp-mediated efflux in HepG2 cells.